For example, Farahmand's CNN model classifier achieved an AUC of 0.80 in the five‐fold cross‐validation, accurately predicting the HER2 status of breast cancer patients and the response to trastuzumab treatment [67]. This evidence concerns the gene ERBB2 and breast carcinoma.